PINK1 type of Early Onset Parkinson’s Disease (EOPD) in Sudanese patients, 2018
الملخص
Background: Parkinson’s Disease (PD) is a neurodegenerative disorder affecting the motor system. It is a chronic progressive disorder that leads to long standing disability.
Objective: To study the presentations and PINK1 gene in young Sudanese patients with PD.
Methods: A prospective study was conducted among 31 PD patients at the National center for Neurological Science (NCNS) at Khartoum state. A structured questionnaire was used for data collection. This consisted of personal data, clinical presentations, and investigations. RT-PCR technique was done using G-spinTM kit. PINK1 gene was detected in most of the samples and was strongly positive. Data was analyzed using SPSS version 21.
Results: The majority of them, 19 (61%), were located in age group 41–50 years; the mean age of onset was 33.4 ± 12 yr; Our of the total number of subjects, 19 (61%) were male and 12 (39%) were female with a ratio 1.6:1 (M:F); 20 (64.5%) were married and 8 (40%) were endogamous married; 5 (62.5%) were second degree and 3 (37.5%) were third degree, 17 (85%) had children and 2 (10%) had children with PD; 22 (71%) had duration more than 12 months and 12 (39%) were more than 40 years old; 29 (93.5%) had tremor, 27 (87.1%) had rigidity, 23 (74.2%) had bradykinesia, and 14 (45%) had positive family history of PD. PINK1 gene expression was detected in 28 (90.3%) patients. No significant associations were found between PINK1 expression and age, gender, age at onset, and family history (P > 0.05).
Conclusion: This study concludes that early onset PD was common among males than females. The most affected age group was found to be 41–50 years and the mean age of onset was 33.4 yr. Also, the patterns of the clinical features were generally similar to literature. PINK1 expression was predominant with no significant associations between PINK1 expression with age, gender, age at onset, and family history.
المراجع
[2] Charcot, J. M. (1879). Lecture V. on paralysis agitans. In: G Sigerson G (trans.), Lectures on diseases of the nervous system. Philadelphia: HC Lea.
[3] Greenfield, J. G. and Bosanquet, F. D. (1953). The brain-stem lesions in Parkinsonism. Journal of Neurology, Neurosurgery, and Psychiatry, vol. 16, pp. 213–226.
[4] Barbeau A. (1962). The pathogenesis of Parkinson’s disease: a new hypothesis. Canadian Medical Association Journal, vol. 87, pp. 802–807.
[5] Birkmayer, W. and Hornykiewicz, O. (1962). The L-dihydroxyphenylalanine (L-DOPA) effect in Parkinson’s syndrome in man: on the pathogenesis and treatment of Parkinson akinesis. Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr, vol. 203, pp. 560–574.
[6] Cotzias, G. C., Van Woert, M. H., and Schiffer, L. M. (1967). Aromatic amino acids and modification of parkinsonism. The New England Journal of Medicine, vol. 276, pp. 374–379.
[7] Speelman, J. D. and Bosch, D. A. (1998). Resurgence of functional neurosurgery for Parkinson’s disease: a historical perspective. Movement Disorders, vol. 13, pp. 582–588.
[8] Jankovic, J. (2001). Parkinson’s disease therapy: treatment of early and late disease. Chinese Medical Journal, vol. 114, pp. 227–234.
[9] Hedrich, K., Hagenah, J., Djarmati, A., et al. (2006). Clinical spectrum of homozygous and heterozygous PINK1 mutations in a large German family with Parkinson disease: role of a single hit? Archives of Neurology, vol. 63, pp. 833–838.
[10] Bonifati, V., Rohé, C. F., Breedveld, G. J., et al. (2005). Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology, vol. 65, pp. 87–95.
[11] Marongiu, R., Ferraris, A., Ialongo, T., et al. (2008). PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum. Human Mutation, vol. 29, p. 565.
[12] Ricciardi, L., Petrucci, S., Guidubaldi, A., et al. (2014). Phenotypic variability of PINK1 expression: 12 Years’ clinical follow-up of two Italian families. Movement Disorders, vol. 29, pp. 1561–1566.
[13] Nishioka, K., Kefi, M., Jasinska-Myga, B., et al. (2010). A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson disease. Journal of Neurology, Neurosurgery, and Psychiatry, vol. 81, pp. 391–395.
[14] Prestel, J., Gempel, K., Hauser, T. K., et al. (2009). Clinical presentation of Parkinson’s disease among Sudanese patients. Sudan Journal of Medical Sciences, vol. 4, no. 3, pp. 47–51.
[15] Witjas, T., Kaphan, E., Azalay, J. P., et al. (2002). Non motor fluctuation in PD frequent and disability. Neurology, vol. 59, pp. 408–413.
[16] Adkin, A. L., Frank, J. S., and Jog, M. S. (2003). Fear of falling and postural control in Parkinson’s disease. Movement Disorders, vol. 18, pp. 496–502.
[17] Bentio-Leon, J., Bermejo-Pareja, F., Rodriguez, J, et al. (2003). Prevalence of PD and
other types of parkinsonism in three elderly populations of central Spain. Movement Disorders, vol. 18, no. 3, pp. 267–274.
[18] Koziorowski, D., Hoffman-Zacharska, D., Sławek, J., et al. (2013). Incidence of mutations in the PARK2 and PINK1 genes in Polish early-onset Parkinson disease patients. Neurologia i Neurochirurgia Polska, vol. 47, no. 4, pp. 319–324.
[19] Piccoli, C., Ripoli, M., Quarato, G., et al. (2008). Coexistence of mutations in PINK1 and mitochondrial DNA in early onset parkinsonism. Journal of Medical Genetics, vol. 45, pp. 596–602.
[20] Al-Mubark, B. R., Bohlega, S. A., Alkhairallah, T. S., et al. (2015). Parkinson disease in Saudi patients. Agenetic study. PLOS ONE.
